bacterico is a biotechnology startup developing personalized healthcare solutions based on an individual’s own gut microbiome. We isolate, select, and cultivate Bifidobacterium strains from stool samples and enhance them using proprietary culture methods to create personalized probiotic supplements optimized for each person’s gut environment. We also provide evidence-based programs tailored to key life moments, including Mama Flora, which supports maternal and infant health through prenatal gut microbiome care, and Preflora, a personalized nutrition and gut-health program designed specifically for individuals who are actively trying to conceive. Through science-driven, individualized interventions, bacterico aims to bring safe and effective microbiome-based solutions to everyday health.
[画像1: https://prtimes.jp/i/111676/2/resize/d111676-2-06f70f0da77fcc8956b1-0.png ] 株式会社bacterico(バクテリコ)は、一人ひとりの腸内フローラのデータに基づいて、自分に合った栄養指導などが専門家か...
[画像1: https://prtimes.jp/i/111676/1/resize/d111676-1-60da72fa9b6a1052da72-0.png ] 「mamaflora」とは、赤ちゃんが生まれる前から健やかな成長を支援することを目指し、一人ひとり異なる腸内細菌データに...

Our key product is Enteral Ventilation (EVA) technology, that supplies liquid oxygen to premature babies with serious respiratory problems through Gut-Mediated Oxygen Delivery. The program is at the clinical trial stage.

A startup has developed a painless, simple test using tears to detect cancer early and monitor for recurrence. Using cutting-edge technology originating from Kobe University, it enables highly sensitive detection of extracellular vesicles, allowing testing in everyday settings like homes or pharmacies.

A startup developing mass-producible platelet preparations using technology to generate platelets from human iPS cells. It aims to provide stable supplies to medical settings in developed and developing countries facing blood donation shortages, thereby supporting transfusion medicine.

【Neoself Platform for Clinical Diagnostics and Drug Development】 AOI Bio leverages a newly discovered mechanism, coined Neoself, underlying autoimmune diseases to provide diagnostic services and to develop novel therapeutics. AOI Bio. currently offers clinical testing for the B2GPI Neoself Antibody in patients with unexplained recurrent pregnancy or implantation failures. 【Bioinformatics Analysis Platform for Drug Discovery】 AOI Bio employs advanced computational methods to identify novel biomarkers and drug candidates. By utilizing industry-leading solutions, such as quantum-optimized allosteric pocket identification, AOI Bio. drives its groundbreaking drug development efforts forward.